Immunovant, Inc. (IMVT): Capital Expenditures
$8.0K
Year ended 2026-03-31
-65.6%
3-year compound annual growth
-48.0%
5-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2026-03-31 | $8.0K | -98.9% | 2026-05-20, From 2025-04-01 |
| 2025-03-31 | $759.0K | +110.8% | 2026-05-20, From 2024-04-01 |
| 2024-03-31 | $360.0K | +82.7% | 2026-05-20, From 2023-04-01 |
| 2023-03-31 | $197.0K | -22.4% | 2025-05-29, From 2022-04-01 |
| 2022-03-31 | $254.0K | +21.0% | 2023-05-22, From 2021-04-01 |
| 2021-03-31 | $210.0K | +577.4% | 2022-06-08, From 2020-04-01 |
| 2020-03-31 | $31.0K | -40.4% | 2021-06-01, From 2019-04-01 |
| 2019-03-31 | $52.0K | n/a | 2020-06-29, From 2018-04-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Immunovant, Inc. (IMVT) | 2026-03-31 | $8.0K | -98.9% |
| Vir Biotechnology, Inc. (VIR) | 2025-12-31 | $4.83M | -33.8% |
| Iovance Biotherapeutics, Inc. (IOVA) | 2025-12-31 | $33.84M | +205.7% |
| Immunocore Holdings plc (IMCR) | 2025-12-31 | $4.34M | -16.1% |
| Ginkgo Bioworks Holdings, Inc. (DNA) | 2025-12-31 | $7.67M | -87.7% |
| Denali Therapeutics Inc. (DNLI) | 2025-12-31 | $9.50M | -40.3% |
| CG Oncology, Inc. (CGON) | 2025-12-31 | $134.0K | -42.7% |
| Krystal Biotech, Inc. (KRYS) | 2025-12-31 | $11.95M | +182.0% |
| Twist Bioscience Corp (TWST) | 2025-09-30 | $28.00M | +451.7% |
Compare IMVT, VIR, IOVA, IMCR side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗